New Technology Set to Transform Clinical Trial
Veridix AI, a division of Emmes Group, has announced the launch of its groundbreaking protocol digitization technology. This new capability is designed to streamline the clinical trial study build process, reducing timelines by up to 30% and improving data accuracy.
Enhancing Clinical Trial Efficiency
Veridix AI’s protocol digitization is integrated into the Advantage eClinical Cloud platform. This advanced technology employs natural language processing (NLP) and artificial intelligence (AI) to convert unstructured clinical trial protocols into structured data elements. These elements include visit schedules, study cohorts, and electronic case report forms (eCRFs). By leveraging historical clinical trial data, Veridix AI’s system can generate visit schedules and predict eCRFs with over 82% accuracy.
Addressing Manual Process Challenges
Traditionally, clinical trial processes have been marred by slow, manual, and error-prone methods. The task of reviewing protocols to extract necessary study elements is no exception. Veridix AI’s new approach addresses these challenges by automating the protocol extraction process, thereby enhancing overall efficiency and data quality.
Rama Kondru, CEO of Veridix AI, remarked, “The digitization of protocols represents a significant advancement in how protocol information is utilised throughout the clinical research lifecycle. By harnessing NLP and AI technologies, we are automating various aspects of the clinical trial process, marking a substantial leap forward in integrating technology into clinical research.”
Future Developments and Impact
Looking ahead, Veridix AI plans to further enhance its capabilities with future releases of Advantage eClinical Cloud. Upcoming features will include an embedded workflow for converting protocols into structured data elements and the automated creation of eCRFs, including edit checks based on AI predictions. These advancements are expected to continue improving the efficiency of clinical trial study builds.
Sastry Chilukuri, CEO of Emmes Group, stated, “This innovative capability significantly accelerates the study build process, allowing our data managers to focus on more valuable tasks rather than on time-consuming manual processes. We have integrated this technology into over 40 new study builds across both our government and commercial projects. This underscores our dedication to advancing clinical trials through next-generation technology and AI.”
Commitment to Innovation
Veridix AI’s introduction of protocol digitization marks a pivotal moment in the evolution of clinical trial technology. By reducing the manual workload and enhancing accuracy, this new capability represents a significant step towards more efficient and reliable clinical trials. The deployment of this technology across a wide range of studies highlights Veridix AI’s ongoing commitment to leveraging advanced technology to improve clinical research outcomes.